Pioneering Medical Innovations
Despite the cloud of questions surrounding its clinical efficacy, an FDA advisory panel overwhelmingly recommended approval for the Sentinel Cerebral Protection System. As a de novo application for a lower-risk device, the Sentinel did not require a formal panel vote.
Claret Medical® today announced the results from the SENTINEL pivotal IDE trial of the Sentinel® Cerebral Protection System (CPS), used to protect patients’ brains during transcatheter aortic valve replacement (TAVR).
Sentinel System Shown to Protect the Vast Majority of Brain Regions from Risk of Cerebral Infarcts; Reduces Number and Volume of
FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to
First-of-its-kind Treatment Offers Significant Clinical Benefits to Prostate Cancer Patients Undergoing Radiotherapy WALTHAM, Mass.—April 2, 2015—Augmenix, Inc., a privately held
— Topline results of the second Phase 3 clinical trial expected by the end of March — — NDA submission
WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Amar Sawhney, Ph.D., CEO,
CAMPBELL, Calif., Jan. 13, 2015 /PRNewswire/ — Apama Medical, Inc., a privately held medical device company focused on the development of
OTX-DP Demonstrated Statistically Significant Therapeutic Effect for Ocular Itching and Conjunctival Redness over Six Weeks with a Single Dose BEDFORD,
DUBLIN, Ohio, Sept. 25, 2014 /PRNewswire/ — AccessClosure, a Cardinal Health company, recently won the Emerging Growth Company Award from Phoenix,